Cargando…

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer

Different anti-PD-1 and anti-PD-L1 antibodies bind different epitopes. However, whether the results from the SP142 and 22C3 immunochemistry (IHC) assays can be interchanged to determine patient eligibility for immunotherapy remains largely unknown. Histologic sections from 135 tumor samples were pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Haipeng, Lin, Gen, Huang, Cheng, Zhu, Weifeng, Miao, Qian, Fan, Xirong, Wu, Biao, Zheng, Xiaobing, Lin, Xiandong, Jiang, Kan, Hu, Dan, Li, Chao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5717240/ https://www.ncbi.nlm.nih.gov/pubmed/29209070 http://dx.doi.org/10.1038/s41598-017-17034-5

Ejemplares similares

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
por: Vennapusa, Bharathi, et al.
Publicado: (2019)

Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
por: Lee, Seung Eun, et al.
Publicado: (2020)

PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
por: Compérat, Eva, et al.
Publicado: (2021)

Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer
por: Lin, Gen, et al.
Publicado: (2017)

PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
por: Evans, Harriet, et al.
Publicado: (2022)

Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
por: Li, Yijin, et al.
Publicado: (2021)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
por: Baek, Seung Ho, et al.
Publicado: (2022)

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms
por: Sigurjonsdottir, Gudbjörg, et al.
Publicado: (2023)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay
por: Danziger, Natalie, et al.
Publicado: (2023)

Concordance of Immunohistochemistry-Based and Gene Expression-Based Subtyping in Breast Cancer
por: Holm, Johanna, et al.
Publicado: (2020)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Mismatch Repair Protein Expression in Endometrial Cancer: Assessing Concordance and Unveiling Pitfalls in Two Different Immunohistochemistry Assays
por: Yoshida, Hiroshi, et al.
Publicado: (2023)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review
por: Sakakibara, Ayako, et al.
Publicado: (2021)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2021)

SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
por: Pang, Jia-Min B., et al.
Publicado: (2021)

Comments on the Article by Miura et al.: “Comparable Clinical Benefit Between Different Subsets Selected by PD-L1 22C3 and SP142 Tests”
por: Yatabe, Yasushi
Publicado: (2023)

Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer
por: He, Jiankun, et al.
Publicado: (2023)

PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
por: Nesline, Mary K., et al.
Publicado: (2023)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

“Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
por: Torlakovic, Emina, et al.
Publicado: (2019)

Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
por: Cerbelli, Bruna, et al.
Publicado: (2021)

Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer
por: Fu, Fangqiu, et al.
Publicado: (2022)

SP142 evaluation contributes to the prediction of immune checkpoint inhibitor efficacy in non-small cell lung cancer with high PD-L1 expression assessed by 22C3
por: Nakahama, Kenji, et al.
Publicado: (2022)

Concordance between Histology, Immunohistochemistry, and RT-PCR in the Diagnosis of Feline Infectious Peritonitis
por: Stranieri, Angelica, et al.
Publicado: (2020)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy
por: Yeong, Joe, et al.
Publicado: (2022)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

Concordance of RT-qPCR with immunohistochemistry and its beneficial role in breast cancer subtyping
por: Li, Yilun, et al.
Publicado: (2023)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
por: Phillips, Therese, et al.
Publicado: (2015)

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group
por: Van Bockstal, Mieke R., et al.
Publicado: (2021)

Relationship between SP142 PD-L1 Expression and (18)F-FDG Uptake in Non-Small-Cell Lung Cancer
por: Zhao, Long, et al.
Publicado: (2020)

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors
por: Guo, Hua, et al.
Publicado: (2020)

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
por: Ilie, Marius, et al.
Publicado: (2017)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qk2o085861apoit2sgpg70nbh8